<DOC>
	<DOC>NCT00516152</DOC>
	<brief_summary>The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fludarabine as preparative therapy and tacrolimus plus methotrexate as the GVHD prophylaxis regimen. The goal is to demonstrate safety, aiming for a transplant related mortality rate (TRM) of &lt; or equal to 40% at 100 days. A TRM of &gt; or equal to 60% will be considered unacceptable. Another goal is to demonstrate efficacy by showing and overall survival of &gt;40% at 1-year following transplant.</brief_summary>
	<brief_title>Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>No fully or singleantigen mismatched sibling donor is available to donate stem cells. Age &gt;15 and &lt;61 ECOG PS &lt; or equal to 2 Adequate renal function with serum creatinine &lt;2.0 mg/dl Pulmonary diffusing capacity &gt;40% of predicted Cardiac ejection fraction &gt;40% as measured by radionuclide wall motion study or echocardiography No active liver disease. Total bilirubin must be &lt; or equal to 2.0 mg/dl. Alkaline phosphatase and AST must be less than three times the upper limit of normal. Patients with hepatitis C and active hepatitis B are eligible only if a liver biopsy is performed and there is &lt; or equal to grade 2 inflammation. Patients wtih a history of HBV infection should be tested for HBeAg, antiHBe and HBV DNA (quantitative). Patients with active HBV viral replication should receive antiviral therapy. Negative serology for the human immunodeficiency virus (HIV) Available HLAmatched donor (see HLA compatibility requirements below) Signed informed consent from the recipient Ongoing active infection Pregnancy and/or nursing Active, uncontrolled CNS leukemia Opinion of BMT Committee that autologous or miniallogeneic transplant would be the preferable form of treatment Receipt of any chemotherapy within 3 weeks of study entry except for hydroxyurea or imatinib mesylate. Use of interferon within 3 months of starting therapy.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Matched Unrelated Donor</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Hematopoietic Disorder</keyword>
</DOC>